Radiation Oncology
Division History
Staff
Contact and Directions
Photos of the Radiation Oncology Division
Events
Research
Patient Information Sessions
Booklet: Preparing for your Treatments
Video: Your Radiotherapy journey
Video: Radiotherapy to the Head & Neck

Thierry M. Muanza, B.A., M.Sc., M.D., FRCP(C)

Dr. Muanza joined the JGH Radiation Oncology Department in 2004. His dedication to his field is undisputed: in addition to his clinical duties, he is an active member of several tumor boards at various medical insitutions. He is an Assistant Professor at McGill University. His research acitivities earned him a FRSQ Chercheur – boursier clinicien Junior 1.  His involovment with the Young Adult Clinic has lead to improved understanding and care for patients in the 18-39 age category.

Medical School
Université de Sherbrooke, Sherbrooke, QC

Internship/Residency
Jewish General Hospital, Montreal, QC

Fellowship
ASTRO-NCI Fellow, National Institutes of Health, Bethesda, MD, USA

Clinical Specialties
Radiation Oncology
CNS Cancer
Breast Cancer
Lung Cancer
Adolescent &Young Adult Oncology (AYA)

Research Interests
Translational Research
Interaction of Ionizing Radiation and Molecular Tartgeted Therapies
Biomarkers
Radiation-induced Normal Tissue Injury
Optical Coherence Tomography

Clinical Research
Breast: IGRT 3D-US, Partial Breast Irradiation, Lymphedema
CNS: Biomarkers, Combined Modality Therapies for high-grade Gliomas, IGRT:Rapid Arc & FSRT
Lung: Biomarkers, Combined Modality Therapies, IGRT, SBRT
AYA: Biomarkers & Quality of Life

Dr. Thierry Muanza
Department of Oncology, Division of Radiation Oncology
Jewish General Hospital
Room G-002
3755 Côte Ste. Catherine Road
Montréal, Québec, H3T 1E2
T: 514-340-8288
F: 54-340-7548

Recent Publications  

Shakir SI, Pelmus M, AncaFlorea, Boileau J-F, Guiot M-C, Di Maio S, Muanza T. Synchronous Metastatic Skull Base Chordoma to the Breast: case report and literature review. Current Oncology. 2016 Apr; 23(2):e154-7.

Maria OM, Kumala S, Heravi M, Syme A, Eliopoulos N, Muanza T. Adipose mesenchymal stromal cells response to ionizing radiation. Cytotherapy. 2016 Mar;18(3):384-401.

NRG Oncology/RTOG 0525 Role of Machine Learning Analytic Tools for Survival Prediction of GBM Patients Using Clinical Parameters. Hao Zhang, Peixin Zhang, Mark Gilbert, Kenneth Aldape, Arnab Chakravarti, Anthony Magliocco, Alexander Klimowicz, Warren D'Souza, Benjamin Corn, Grant Hunter, Thierry Muanza, Adam Dicker, Eric Vigneault, David Brachman, Joseph Bovi, H. Ian Robins, Walter Sahijdak, Minhee Won, Minesh Mehta. ASTRO 57th Annual Scientific Meeting, October 18-21 in San Antonio, Tx, USA.Presentation #: 324. International Journal of Radiation Oncology * Biology * Physics Vol. 93 (3S), Page S142, ASTRO 2015.

Randomized Clinical Trial of a Progressive Exercise Program for Young Women With Breast Cancer Undergoing Radiation Therapy. Thierry Muanza, Marize Ibrahim, Beatrice Fournier, Mary-Ann Dalzell, Shirin Shallwani, Anouline Sintharaphone, Warren Sateren. ASTRO 57th Annual Scientific Meeting,October 18-21 in San Antonio, Tx, USA.Presentation #: 79. International Journal of Radiation Oncology * Biology * Physics Vol. 93 (3S), Page S35, ASTRO 2015.

Novel binary molecule ZRBA1, as a unique MGMT independent radiosensitizer to treat malignant Gliomas. T. Muanza, S. Kumala, M. Heravi, H. Bekerat, M. S. Sadr, R. Del maestro, B. Jean-Claude. CARO 2015 Annual Scientific Meeting, September 9-12, 2015, Kelowna BC, Canada. Abstract # 63. Radiotherapy & Oncology: 116 (S. 1), September 2015.

Single Institute Experience of using On Line Radiotherapy Plan Evaluator Tool for Stereotactic Radiosrugery. S. Shakir, K. Sultnamen, T. Muanza, G. Stroian, F. De Blois, M. Fan. CARO 2015 Annual Scientific Meeting, September 9-12, 2015, Kelowna BC, Canada. Abstract # 219. Radiotherapy & Oncology: 116 (S. 1), September 2015.

Mitra Heravi, Slawomir Kumala, Zakaria Rachid, Nada Tomic, Slobodan Devic, Bertrand J. Jean-Claude, Danuta Radzioch and Thierry M. Muanza. ZRBA1, a Mixed EGFR/DNA Targeting Molecule, Potentiates Radiation Response Through Delayed DNA Damage Repair Process in a Triple Negative Breast Cancer Model. International Journal of Radiation Oncology*Biology*Physics. Volume 92(2): 399-406. June 2015

Alshami J, Guiot M-C, Owen S, Kavan P, Gibson N, Solca F, Cseh A, Reardon D, Muanza T. Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report. Oncotarget. 2015 Oct 20;6(32):34030-7. doi: 10.18632/oncotarget.5297

Interim Analysis of the EF-14 Trial: A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM. Roger Stupp, Eric Wong, Charles Scott, Sophie Taillibert, Andrew Kanner, Santosh Keesari and Zvi Ram on behalf of the EF-14 Trial investigators. 19th Annual Scientific Meeting of the Society for Neuro-Oncology, November 15, 2014, Miami, USA. Abstract ID: NT-40 Neuro Oncol 2014 Nov; 16(Suppl 5): 1-241.

M.B. Azam1, Y.S. Rho1, A. Mamo1, S. Sahebjam2, T. Muanza1, M.-C. Guiot1, J. Al-Shami1, R. Sharma1, P. Kavan1; 1Montreal, QC/CA, 2Tampa, FL/US. Patterns and efficacy of bevacizumab use across treatment lines in glioblastoma. ESMO 2014 Congress, 26-30 September, Madrid, Spain. Abstract ID: 8222, Annals of Oncology.

Niazi T, Mok G, Heravi M, Vuong T, Aloyz R, Panasci L, Muanza T.  Effects of DNA-PK inhibition
on DNA repair and cell survival in irradiated gastric cancer cell line N87
.  Current Oncology 2014 Apr;21(2):91-6.

Sahebjam S, Garoufalis E, Guiot M C, Muanza T,Del Maestro R, Petrecca K, Sharma R, Kavan P. Bevacisumab Use for Recurrent High-Grade Gioma at Mc Gill University Hospital  Can J Neurol Sci. 40:241-246, 2013.

Krauze AV, Won M, Graves C, Corn BW, Muanza TM, Howard SP, Mahadevan A, Schultz CJ, Haas ML, Mehta MP, Camphausen KA.  Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM). Biomark Res. 2013 Oct 31;1(1):29.  

Heravi M, Tomic N, Liang L, Devic S, Holmes J, Deblois F, Radzioch D, Muanza T. Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model. Anticancer Drugs. June 2012, 23(5):525-33

Wong P, Muanza T, Hijal T, Masse L, Pillay S, Chasen M, Lowensteyn I, Gold M, Grover S. Effect of exercise in reducing breast and chest-wall pain in patients with breast cancer: a pilot study, Current Oncology, June 2012, 19(3):e129-35 

Wu X, Kasymjanova G, Holcroft C, Mekouar H, Carbonneau A,  Sultanem K, Muanza T, Her2 and Basal like subtypes of invasive breast cancer are associated with a higher tumor grade and rate of lymph node metastasis, 26th Annual Scientific Meeting CARO 2012 Targeting Biology, September 12-15, 2012, Ottawa, Canada, Radiotherapy & Oncology 104(S2): S94, Abstract #239

Muanza T, Heravi M, Radzioch D, Time and sequence dependency of Sorafenib in combination with ionizing radiation in metastatic breast cancer model,  26th Annual Scientific Meeting CARO 2012 Targeting Biology, September 12-15, 2012, Ottawa, Canada, Radiotherapy & Oncology 104(S2): S2, Abstract #5

Bevacizumab (bev) for recurrent high-grade glioma (HGG): Canadian experience. P. Kavan, S. Sahebjam, M.C. Guiot, E. Garafoulis, T. Muanza, R. Del Maestro. 15th Biennial Canadian Neuro-Oncology Meeting, February 9-11, 2012, Vancouver, Canada. Canadian Journal of Neurological Sciences 39(1): S1-15, abstract # c4.